ArticleScientific reports2025
Cohesive data analysis for the identification of prognostic hub genes and significant pathways associated with HER2 + and TN breast cancer types.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Host immune network-guided reverse vaccinology approach for prioritizing candidate antigens in Schistosoma japonicum-associated liver fibrosis.PLoS neglected tropical diseases · 2026Article
- Ferroptosis in Recurrent Vulvovaginal Candidiasis Through Integrated Bioinformatics and Experimental Validation.Antioxidants (Basel, Switzerland) · 2026Article
- Integrated analysis of Corylin from Psoralea Corylifolia inhibiting osteoporosis via MAPK pathway.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Breast cancer is the most prevalent and lethal form of cancer being the utmost common medical concern of women. Breast cancer etiology implicates numerous cellular protein receptors such as estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor/receptor 2 (HER2) which turn on oncogenic cascade often attributed to certain genetic variations. Breast Cancer is thus classified into ER + /-, PR + /-, HER2 ± and Triple Negative types. This study seeks to build upon our current knowledge of HER2 + and TNBC BC types to discover novel patterns for diagnosis and prognosis. The study exploits wealth of HER2 + and TNBC transcriptome (RNA Seq) data to elucidate the key hub genes, their associated networks, pathways, stage-wise expression profile, role in prognosis and survival expectancy, and regulatory transcription factors. The study also employs machine learning models including support vector machine (SVM), XGBoost, Random Forest, k nearest neighbor (kNN), Naïve Bayes and Voting Classifier to distinguish between HER2 + and TNBC transcriptomes which is a key variable for early detection and choice of therapeutic alternatives. RNA Seq datasets consisting of 49 HER2 + and 44 TNBC breast tumor samples were retrieved and pre-processed. Differentially Expressed Genes (DEGs) along with their logFC and p-values were fetched. The KEGG (Kyoto Encyclopedia of Genes and Genomes) and GO (Gene Ontology) analyses of DEGs were conducted on DAVID (the Database for Annotation, Visualization and Integrated Discovery) and interaction network was constructed through Cytoscape. Ten hub genes were obtained based on maximum clique centrality (MCC), maximum neighborhood component (MNC), degree, closeness and betweenness using cytoHubba which included ACTB, ATM, ESR1, GAPDH, HNRNPK, KRAS, MDM2, SIRT1, TP53, and H3F3C (H3-5). These hub genes were found to be associated with cell proliferation, invasion and migration. Transcription factors and association of the expression profile of these hub genes with survival expectancy was also determined. Among the ML models, SVM stood out, exhibiting classification success between HER2 + and TNBC transcriptomes with an accuracy of 90%. The findings of this study can therefore effectively aid in tracing the initial prognosis of BC and identify biomarkers for the personalized prevention, prediction, diagnosis, and treatment of BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.